In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to detect Protected dosing routine. Additional contributors will likely be enrolled within the identified monotherapy dosign regimen. In Segment B, individuals will get oral ruxolitinib and ABBV-744 will be provided as "insert-on" therapy. In Segment C, https://abbv-744-in-the-treatment46801.blogsumer.com/31323293/the-best-side-of-abbv-744-clinical-trial-phase-1-results